Blepharitis Pipeline Review, H1 2020 –

DUBLIN–(BUSINESS WIRE)–The “Blepharitis Pipeline Review, H1 2020” drug pipelines has been added to’s offering.

Blepharitis Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Blepharitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Blepharitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Blepharitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 7 respectively.

Blepharitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Blepharitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Blepharitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Blepharitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Blepharitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Blepharitis (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Blepharitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Blepharitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Aerie Pharmaceuticals Inc.
  • Azura Ophthalmics Ltd.
  • Formosa Pharmaceuticals Inc.
  • Hovione FarmaCiencia S.A.
  • Merck & Co Inc.
  • NicOx S.A.
  • Novaliq GmbH
  • Premark Pharma GmbH
  • Quorum Innovations LLC
  • Surface Pharmaceuticals Inc.
  • Tarsus Pharmaceuticals Inc.

Key Topics Covered

  1. Introduction
  2. Report Coverage
  3. Blepharitis – Overview
  4. Blepharitis – Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Blepharitis – Therapeutics Assessment
  9. Blepharitis – Companies Involved in Therapeutics Development
  10. Blepharitis – Drug Profiles
  11. Blepharitis – Dormant Projects
  12. Blepharitis – Product Development Milestones

Featured News & Press Releases

  • Dec 19, 2019: Nicox’s NCX 4251 meets primary endpoint in phase 2 blepharitis trial and shows promising efficacy in dry eye disease
  • Sep 27, 2019: Nicox completes enrolment of NCX 4251 phase 2 trial with top-line results on track for Q4 2019
  • Mar 19, 2019: Nicox initiates phase 2 trial of NCX 4251 in Blepharitis
  • Mar 18, 2019: Nicox poster presentation at AGS 2019 Annual Meeting Discloses preclinical data for NCX 4251, a novel blepharitis therapy
  • Mar 12, 2019: Nicox announces presentations including drug candidate NCX 4251 at upcoming scientific conferences
  • Jan 29, 2019: Nicox announces U.S. FDA acceptance of Investigational New Drug Application for NCX 4251 phase 2 trial in Blepharitis

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900